REP 3123

structure in first source

Also Known As:

5-((3-(((4r)-6,8-dibromo-3,4-dihydro-2h-1-benzopyran-4-yl)amino)propyl)amino)thieno(3,2-b)pyridin-7(4h)-one; CRS3123; REP-3123; REP3123; thieno(3,2-b)pyridin-7(4h)-one, 5-((3-(((4r)-6,8-dibromo-3,4-dihydro-2h-1-benzopyran-4-yl)amino)propyl)amino)-

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Thiophenes: 257
    - REP 3123: 4
  - Pyrans: 130
    - Benzopyrans: 195
      - REP 3123: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - REP 3123: 4
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - REP 3123: 4

Experts

1.	Janjic, Nebojsa: 3 articles (01/2017 - 05/2009)
2.	Ochsner, Urs A: 3 articles (01/2017 - 05/2009)
3.	Bell, Stacie J: 2 articles (01/2017 - 05/2009)
4.	Jarvis, Thale C: 2 articles (01/2017 - 05/2009)
5.	Critchley, Ian A: 2 articles (05/2009 - 05/2009)
6.	Young, Casey L: 2 articles (05/2009 - 05/2009)
7.	An, Amanda T: 1 article (01/2017)
8.	Blumer, Jeffrey: 1 article (01/2017)
9.	Gray, Wesley: 1 article (01/2017)
10.	Griffiss, J McLeod: 1 article (01/2017)

Related Diseases

1.	Clostridium Infections 05/01/2009 - "The aim of this study was to characterize the antimicrobial profile of REP3123, a novel inhibitor of methionyl-tRNA synthetase (MetRS) in development for the treatment of Clostridium difficile infection. " 05/01/2009 - "Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections." 05/01/2009 - "REP3123 is a fully synthetic methionyl-tRNA synthetase inhibitor in pre-clinical development as a novel agent to treat Clostridium difficile infection (CDI). "
2.	Infections 05/01/2009 - "Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model." 05/01/2009 - "difficile infection and 223 other intestinal normal flora anaerobes were tested for their susceptibility to REP3123 and four or five comparator agents by the agar dilution method using supplemented Brucella agar with 5% laked sheep blood. "
3.	Hypersensitivity (Allergy) 01/01/2017 - "There were no serious adverse events or immediate allergic reactions during administration of CRS3123. "

Related Drugs and Biologics

1.	Methionine-tRNA Ligase
2.	Anti-Bacterial Agents (Antibiotics)
3.	Agar